What does Aisling Capital Management LP hold? Q1 2026 13F Holdings & Portfolio

AI Analysis · Q1 2026 · Q1 2026

Comprehensive Analysis of Aisling Capital Management LP SEC 13F Filing

1. Portfolio Overview

Aisling Capital Management LP manages a highly concentrated portfolio valued at approximately $375.26 million as of the report date September 30, 2025. The firm employs a high-conviction investment strategy characterized by extreme concentration in the healthcare sector. The portfolio consists of only 11 holdings, indicating a preference for selectivity over broad diversification.

During t...

Quarter at a glance — Q1 2026

Position-change comparison pending.

No quarter-over-quarter changes available.

Top 10 holdings

By portfolio weight as of Q1 2026.

#HoldingValueSharesWeight

BBIO

BridgeBio Pharma Inc. (BBIO)

$378M5.1M79.4%

SNDX

Syndax Pharmaceuticals, Inc. (SNDX)

$31M1.3M6.5%

GLUE

Monte Rosa Therapeutics Inc (GLUE)

$26M1.6M5.4%

BCAX

Bicara Therapeutics Inc. (BCAX)

$11M569K2.4%

BBOT

BridgeBio Oncology Therapeutics (BBOT)

$9M1.0M1.9%

CMPS

Compass Pathways Plc (CMPS)

$8M1.4M1.7%

SRRK

Scholar Rock Holding Corporation (SRRK)

$4M77K0.8%

BMEA

Biomea Fusion Inc (BMEA)

$3M2.0M0.7%

EPRX

Eupraxia Pharmaceuticals Inc. (EPRX)

$2M325K0.5%

M96088105

Urogen Pharma Ltd. (URGN)

$2M108K0.4%

Filing history

Filing history loading…